|
Antonio Lee Ph.D.
Global President
MEDIPOST
Seoul
Korea
|
Dr. Antonio Lee is the Global President at MEDIPOST Korea and also serves as the Co-CEO for MEDIPOST America Inc. and EVASTEM Corp., wholly-owned U.S. and Japanese subsidiaries of MEDIPOST, respectively. Dr. Lee leads MEDIPOST’s global commercialization and clinical development strategy of human Umbilical Cord Blood (hUCB)-derived Mesenchymal Stem/Stromal Cell technology and products including the World’s First regulatory-approved allogeneic hUCB-MSC product - CARTISTEM®, for the treatment of knee Osteoarthritis (OA). Since market-launch in 2012, over 30,000 patients with knee OA received CARTISTEM® treatment in Korea, and a Phase 3 clinical trial is currently in progress in Japan and the Phase 3 clinical trial in the U.S will commence in 2024.